{"schema_version":"1.0","type":"article","title":"美國放行6種胜肽針，瘦瘦針劇本重演","url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook.md","lang":"zh-Hant","date":"2026-11-04","publish_at":"2026-11-04T08:00:00+08:00","updated_at":"2026-11-04","category":"商業分析系列","topic":"商業分析系列","tags":["胜肽","BPC-157","Hims & Hers","調劑藥局","瘦瘦針"],"summary":"美國衛生部 10 月 28 日簽署臨時政策，暫不取締調劑藥局配製 BPC-157 等六種沒有藥證的胜肽。隔天 Hims & Hers 就開了胜肽專區候補名單，走的是複方瘦瘦針同一條通路；在台灣，未經核准輸入的藥品仍屬禁藥。","key_points":["美國衛生部長小羅勃甘迺迪 10 月 28 日簽署臨時政策，暫不取締調劑藥局配製 BPC-157、TB-500 等六種胜肽；這不是 FDA 核准，FDA 職業科學家事前建議全部不要列入。","Hims & Hers 10 月 29 日公布 Peptides+ 預覽，BPC-157 與 TB-500 列為「法規允許時」加入；這家公司今年 3 月才把減重生意從複方 semaglutide 轉向 Novo 原廠藥。","台灣藥事法第 22 條把未經核准擅自輸入的藥品歸為禁藥；美國的放行只是不取締，效力出不了美國。"],"facts":[{"claim":"HHS 臨時政策簽署日","value":"2026-10-28","unit":"日期","as_of":"2026-10-28","source":"The Peptide Rush Has Begun｜TIME"},{"claim":"聯邦公報刊登日","value":"2026-10-30","unit":"日期","as_of":"2026-10-30","source":"5 Things to Know About HHS's Interim Peptide Compounding Policy｜AJMC"},{"claim":"政策涵蓋胜肽數","value":"6","unit":"種","as_of":"2026-10-30","source":"5 Things to Know About HHS's Interim Peptide Compounding Policy｜AJMC"},{"claim":"政策條件數","value":"10","unit":"條","as_of":"2026-10-30","source":"Peptides: HHS Announces Limited Enforcement Discretion｜Foley & Lardner"},{"claim":"公眾意見截止日","value":"2026-11-13","unit":"日期","as_of":"2026-10-30","source":"Peptides: HHS Announces Limited Enforcement Discretion｜Foley & Lardner"},{"claim":"顧問委員會明年再審胜肽數（2 月）","value":"5","unit":"種","as_of":"2026-10-29","source":"5 Things to Know About HHS's Interim Peptide Compounding Policy｜AJMC"},{"claim":"7 月會議前 FDA 新任命委員","value":"8","unit":"名","as_of":"2026-10-29","source":"HHS will permit compounding of six peptides ahead of formal rulemaking｜RAPS"},{"claim":"遠距醫療網站胜肽月費","value":"199–249","unit":"美元／月","as_of":"2026-10-28","source":"The Peptide Rush Has Begun｜TIME"},{"claim":"胜肽市場分析師估計","value":"33","unit":"億美元","as_of":"2026-10-28","source":"The Peptide Rush Has Begun｜TIME"},{"claim":"Hims Peptides+ 預覽公布日","value":"2026-10-29","unit":"日期","as_of":"2026-10-29","source":"Expanding Safe Access to Peptides｜Hims & Hers Newsroom"},{"claim":"Hims 轉向原廠 GLP-1 宣布日","value":"2026-03-09","unit":"日期","as_of":"2026-03-09","source":"Hims & Hers Announces Strategic Shift for US Weight Loss Business｜Hims & Hers IR"},{"claim":"Hims 進入美國減重市場年份","value":"2023","unit":"年","as_of":"2026-03-09","source":"Hims & Hers Announces Strategic Shift for US Weight Loss Business｜Hims & Hers IR"},{"claim":"Hims 第三季財報日","value":"2026-11-09","unit":"日期","as_of":"2026-10-12","source":"Hims & Hers to Announce Third Quarter 2026 Financial Results｜Hims & Hers IR"},{"claim":"BPC-157 人體研究","value":"3 個無對照試驗，合計 30","unit":"人","as_of":"2026-07-01","source":"Heal or Harm? BPC-157 in the Gray Zone｜Pharmacy Times"},{"claim":"WADA 禁用 BPC-157 年份","value":"2022","unit":"年","as_of":"2026-07-01","source":"Heal or Harm? BPC-157 in the Gray Zone｜Pharmacy Times"},{"claim":"台灣減重 LINE 群組成員","value":"2,000+","unit":"人","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"Mounjaro 台灣灰市轉手價","value":"9,500–15,000","unit":"新台幣","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"食藥署 2024 年起稽查藥局診所","value":"487","unit":"家","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"稽查違規家數","value":"85","unit":"家","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"稽查罰款","value":"260","unit":"萬新台幣","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"},{"claim":"藥事法第 82 條禁藥輸入最重刑","value":"10 年徒刑、1 億元罰金","unit":"—","as_of":"2026-01-19","source":"揭開台灣「瘦瘦針」的非法流通網路｜報導者"}],"sections":["01｜放行的不是藥證，是「不取締」","02｜Hims 排隊的，是瘦瘦針那一套","03｜反方：FDA 自己的科學家建議不要","04｜台灣：美國放行，帶回台灣還是禁藥","05｜六種胜肽，換來一條新通路","參考資料"],"references":[{"title":"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances","source":"美國聯邦公報（HHS","date":"2026-10-30","url":"https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances"},{"title":"July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee","source":"美國 FDA","date":"2026-07-23","url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"},{"title":"5 Things to Know About HHS's Interim Peptide Compounding Policy","source":"AJMC","date":"2026-10-29","url":"https://www.ajmc.com/view/5-things-to-know-about-hhs-s-interim-peptide-compounding-policy"},{"title":"HHS will permit compounding of six peptides ahead of formal rulemaking","source":"RAPS Regulatory Focus","date":"2026-10-29","url":"https://www.raps.org/resource/hhs-will-permit-compounding-of-six-peptides-ahead-of-formal-rulemaking.html"},{"title":"Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides","source":"Foley & Lardner","date":"2026-10-30","url":"https://www.foley.com/insights/publications/2026/10/peptides-hhs-announces-limited-enforcement-discretion-for-compounding-of-six-peptides/"},{"title":"The Peptide Rush Has Begun","source":"TIME","date":"2026-10-28","url":"https://time.com/article/2026/10/28/peptide-rush-has-begun/"},{"title":"Starting Today, These Six Peptides Are Back","source":"Dr. Jesse Morse Substack","date":"2026-10-30","url":"https://drjessemorse.substack.com/p/starting-today-these-six-peptides"},{"title":"Expanding Safe Access to Peptides","source":"Hims & Hers Newsroom","date":"2026-10-29","url":"https://news.hims.com/newsroom/expanding-safe-access-to-peptides"},{"title":"Hims & Hers Announces Strategic Shift for US Weight Loss Business","source":"Hims & Hers IR","date":"2026-03-09","url":"https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx"},{"title":"Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026","source":"Hims & Hers IR","date":"2026-10-12","url":"https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-Third-Quarter-2026-Financial-Results-on-November-9-2026/default.aspx"},{"title":"Heal or Harm? Body Protective Compound-157 in the Gray Zone","source":"Pharmacy Times","date":"2026-07-01","url":"https://pharmacytimes.com/view/heal-or-harm-body-protective-compound-157-in-the-gray-zone"},{"title":"社群販售、藥局私賣、日本代購：揭開台灣「瘦瘦針」的非法流通網路","source":"報導者","date":"2026-01-19","url":"https://www.twreporter.org/a/illicit-drug-distribution-of-glp-1-gip-in-taiwan-1"}],"images":[{"alt":"圖1｜從禁用到放行：六種胜肽的一年","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook/figure-01.png"},{"alt":"圖2｜胜肽生意怎麼走：和複方瘦瘦針同一條路","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook/figure-02.png"},{"alt":"圖3｜證據有多薄：以 BPC-157 為例","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook/figure-03.png"},{"alt":"圖4｜同一管胜肽，美國和台灣差在哪","url":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-04）。美國放行6種胜肽針，瘦瘦針劇本重演。https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}